In this edition, difficult-to-treat psoriatic arthritis 'not all about the therapies', Samsung biosimilar comparable to etanercept and more. Read the full coverage here: Difficult-to-treat psoriatic arthritis 'not all about the therapies' Samsung biosimilar comparable to etanercept for psoriatic arthritis outcomes at 1 year Boehringer Ingelheim, Quallent partner to expand Humira biosimilar access VIDEO: Mitigating risk for psoriatic arthritis in patients with psoriasis FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo References: Healio Interview Łosińska K, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25345. Ogdie-Beatty A. Psoriatic Arthritis in 2024. Presented at The Congress of Clinical Rheumatology East; May 9-12, 2024; Destin, Florida (hybrid meeting). Press Release Press Release

Ver todos los episodios